Financial Performance - Revenue for the year ended December 31, 2024, was approximately HKD 3,359,416,000, a slight increase from HKD 3,338,429,000 in 2023[3] - Profit attributable to owners of the company was approximately HKD 548,069,000, down from HKD 635,634,000 in the previous year, representing a decrease of about 13.8%[3] - Basic earnings per share decreased to HKD 0.5109 from HKD 0.5925, reflecting a decline of approximately 13.5%[3] - The net profit for the year was HKD 801,165,000, down from HKD 982,537,000 in 2023, indicating a decrease of about 18.4%[5] - Other comprehensive income for the year was a loss of HKD 626,900,000, compared to a gain of HKD 234,211,000 in the previous year[5] - The annual profit for 2024 reached HKD 548,069,000, a decrease of 13.75% compared to HKD 635,634,000 in 2023[23] Dividends - The proposed final dividend is HKD 0.0882 per share, leading to a total annual dividend of HKD 0.14 per share, an increase of approximately 14.3% compared to HKD 0.1225 in 2023[3] - The interim dividend for 2024 was set at HKD 5.18 per share, compared to HKD 3.45 per share in 2023, representing a 50.15% increase[24] - The total dividends declared for the year amounted to HKD 149,973,000, up from HKD 96,013,000 in 2023, indicating a growth of 56.25%[24] - The company proposed a final dividend of HKD 8.82 per share for the year ending December 31, 2024, compared to HKD 8.80 per share in 2023, a slight increase of 0.23%[24] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 22,192,849,000, a slight decrease from HKD 22,292,679,000 in 2023[7] - Current liabilities increased to HKD 4,494,073,000 from HKD 2,827,869,000, indicating a significant rise in short-term obligations[7] - The company's total equity decreased to HKD 17,455,293,000 from HKD 17,512,928,000, reflecting a decline of approximately 0.3%[7] - Total liabilities as of December 31, 2024, were HKD 4,737,556,000, down from HKD 4,779,751,000 in 2023[16] Segment Performance - The operating profit (loss) before interest for the utilities segment is HKD 30,579,000, while the pharmaceuticals segment shows a significant operating profit of HKD 491,053,000[13] - Revenue from external customers in the utilities segment was HKD 1,599,849,000, while the medical segment generated HKD 1,441,437,000[14] - Revenue from the water supply segment decreased by 2.2% to approximately HKD 304,300,000, while profit increased by 8.1% to HKD 17,300,000 due to reduced administrative expenses[36] - Revenue from the thermal energy segment decreased by 11.6% to approximately HKD 1,139,400,000, with profit dropping to HKD 24,700,000 from HKD 35,900,000, primarily due to a reduction in government subsidies[37] - The electricity segment reported revenue of approximately HKD 2,399,400,000, a decrease of 4.2%, with profit contribution falling to HKD 57,500,000 from HKD 63,000,000[38] - Pharmaceutical segment revenue increased by 11.7% to approximately HKD 1,609,700,000, driven by a 14.8% increase in sales of chemical and traditional Chinese medicines[39] Investments and Financial Management - The company recognized a gain of approximately HKD 350,233,000 due to the dilution of its interest in a joint venture, reflecting a significant financial impact[25] - The fair value of listed equity securities decreased to HKD 84,228,000 in 2024 from HKD 99,952,000 in 2023, a decline of 15.73%[26] - The non-listed equity securities increased to HKD 2,181,392,000 in 2024 from HKD 1,619,566,000 in 2023, reflecting a growth of 34.67%[26] - The group employed approximately 2,729 employees as of December 31, 2024, an increase from 2,376 employees in 2023[55] Compliance and Governance - The financial statements for the two years received an unqualified opinion from the independent auditor, indicating no significant issues[9] - The company has not early adopted any new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective[11] - The group has complied with the corporate governance code as per the listing rules throughout the year[61] - The audit committee consists of four independent non-executive directors who regularly review the group's accounting principles and risk management[64] Future Outlook - The company expects stable economic development in China despite external uncertainties, emphasizing a commitment to prudent financial management and business integration[51] - The company plans to continue expanding its market presence in China, where revenue was HKD 3,225,190,000, slightly up from HKD 3,208,051,000 in 2023[17]
天津发展(00882) - 2024 - 年度业绩